

# Alissa Visram

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5842037/publications.pdf>

Version: 2024-02-01

34  
papers

174  
citations

1162889

8  
h-index

1199470

12  
g-index

35  
all docs

35  
docs citations

35  
times ranked

279  
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes after biochemical or clinical progression in patients with multiple myeloma. <i>Blood Advances</i> , 2023, 7, 909-917.	2.5	7
2	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. <i>Leukemia</i> , 2022, 36, 1058-1065.	3.3	3
3	Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio $\geq 100$ . <i>Leukemia</i> , 2022, 36, 1429-1431.	3.3	8
4	Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	0
5	Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota. <i>Blood Cancer Journal</i> , 2022, 12, 67.	2.8	13
6	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 274-277.	1.3	1
7	Outcomes of multiple myeloma patients with $\langle scp \rangle \text{del } 17p \langle /scp \rangle$ undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2021, 96, E35-E38.	2.0	2
8	Autologous stem cell transplantation for multiple myeloma patients aged $\geq 75$ treated with novel agents. <i>Bone Marrow Transplantation</i> , 2021, 56, 1144-1150.	1.3	15
9	Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 309.e1-309.e5.	0.6	1
10	Retroperitoneal involvement with light chain amyloidosis- case series and literature review. <i>Leukemia and Lymphoma</i> , 2021, 62, 316-322.	0.6	2
11	Practical management and assessment of primary plasma cell leukemia in the novel agent era. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100414.	0.7	1
12	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. <i>Leukemia</i> , 2021, 35, 1428-1437.	3.3	8
13	Relapsed multiple myeloma demonstrates distinct patterns of immune microenvironment and malignant cell-mediated immunosuppression. <i>Blood Cancer Journal</i> , 2021, 11, 45.	2.8	24
14	Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. <i>Blood Cancer Journal</i> , 2021, 11, 120.	2.8	18
15	Treatment and outcome of newly diagnosed multiple myeloma patients $\geq 75$ years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 3011-3018.	0.6	2
16	Ageing-associated immune system changes in multiple myeloma: The dark side of the moon.. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100494.	0.7	6
17	Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , 2021, 138, 2700-2700.	0.6	0
18	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio $\geq 100$ . <i>Blood</i> , 2021, 138, 1617-1617.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. <i>Blood Cancer Journal</i> , 2021, 11, 186.	2.8	8
20	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 3760-3760.	0.6	1
21	Prognostic Factors for Early (&lt;2 years) and Late (&gt;5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. <i>Blood</i> , 2021, 138, 3761-3761.	0.6	0
22	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. <i>Blood</i> , 2021, 138, 543-543.	0.6	0
23	Colon perforation in multiple myeloma patients – A complication of high-dose steroid treatment. <i>Cancer Medicine</i> , 2020, 9, 8895-8901.	1.3	3
24	Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studies. <i>Leukemia Research</i> , 2020, 97, 106442.	0.4	15
25	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020, 10, 124.	2.8	12
26	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 596-601.	0.2	15
27	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients &gt; 75 Years Old: A Retrospective Analysis. <i>Blood</i> , 2020, 136, 14-15.	0.6	0
28	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 21-22.	0.6	0
29	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged &#x2264; 75 Treated with Novel Agents. <i>Blood</i> , 2020, 136, 12-13.	0.6	0
30	Retroperitoneal Involvement of Light Chain Amyloidosis-Case Series and Literature Review. <i>Blood</i> , 2020, 136, 37-38.	0.6	0
31	Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. <i>Blood</i> , 2020, 136, 1-2.	0.6	0
32	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 41-42.	0.6	0
33	Describing the Cellular and Humoral Immune Tumor Microenvironment and Malignant Transcriptome across the Multiple Myeloma Disease Spectrum. <i>Blood</i> , 2020, 136, 39-40.	0.6	2
34	Effect of Donor Age and Donor Relatedness on Time to Allogeneic Hematopoietic Cell Transplantation in Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2466-2470.	2.0	7